Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Enterprise Value (2024 - 2025)

Prelude Therapeutics' Enterprise Value history spans 2 years, with the latest figure at -$103.2 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 22.75% year-over-year to -$103.2 million; the TTM value through Dec 2025 reached -$103.2 million, up 22.75%, while the annual FY2025 figure was -$103.2 million, 22.75% up from the prior year.
  • Enterprise Value for Q4 2025 was -$103.2 million at Prelude Therapeutics, down from -$58.2 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$58.2 million in Q3 2025 and bottomed at -$206.0 million in Q1 2024.